Efficacy of naproxen prophylaxis for the prevention of heterotopic ossification after hip surgery: a meta-analysis
- PMID: 29506541
- PMCID: PMC5839069
- DOI: 10.1186/s13018-018-0747-8
Efficacy of naproxen prophylaxis for the prevention of heterotopic ossification after hip surgery: a meta-analysis
Abstract
Background: This meta-analysis aimed to assess whether the specific nonsteroidal anti-inflammatory drug (NSAID) naproxen has a role in reducing the occurrence of heterotopic ossification after hip surgery.
Methods: Potential studies were identified in the following electronic databases: PubMed, EMBASE, Web of Science, Cochrane Library, and Google. We included studies involving hip surgery patients in which the intervention group received naproxen and the control group received placebo. The occurrence of heterotopic ossification and complications were the final outcomes. Stata 13.0 was used for the meta-analysis.
Results: Four randomized controlled trials (RCTs) involving 269 patients were ultimately included in this meta-analysis. The use of naproxen was associated with a significant reduction in the occurrence of heterotopic ossification at 1.5-, 3-, 6-, and 12-month follow-ups (P < 0.05). There was no significant difference in the occurrence of complications between treatment and control groups (P > 0.05).
Conclusion: Our analysis indicates that naproxen can decrease the occurrence of heterotopic ossification without increasing complications in hip surgery patients. Due to the limited number of studies included, more high-quality RCTs are needed to identify the optimal dose of naproxen.
Keywords: Heterotopic ossification; Hip surgery; Meta-analysis; Naproxen.
Conflict of interest statement
Author contributions
RM and GHC conceived the study design. LJZ and XCZ performed the study, collected the data, and contributed to the study design. LJZ and XCZ prepared the manuscript. RM, GHC, and XCZ edited the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
None
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
